182 related articles for article (PubMed ID: 26916006)
21. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
Proia DA; Bates RC
Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
[TBL] [Abstract][Full Text] [Related]
22. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
Messaoudi S; Peyrat JF; Brion JD; Alami M
Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
[TBL] [Abstract][Full Text] [Related]
23. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.
Kumalo HM; Bhakat S; Soliman ME
Chem Biol Drug Des; 2015 Nov; 86(5):1131-60. PubMed ID: 25958815
[TBL] [Abstract][Full Text] [Related]
24. Anti-Hsp90 therapy in autoimmune and inflammatory diseases: a review of preclinical studies.
Tukaj S; Węgrzyn G
Cell Stress Chaperones; 2016 Mar; 21(2):213-8. PubMed ID: 26786410
[TBL] [Abstract][Full Text] [Related]
25. Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation.
Jaeger AM; Stopfer L; Lee S; Gaglia G; Sandel D; Santagata S; Lin NU; Trepel JB; White F; Jacks T; Lindquist S; Whitesell L
Clin Cancer Res; 2019 Nov; 25(21):6392-6405. PubMed ID: 31213460
[TBL] [Abstract][Full Text] [Related]
26. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
Solárová Z; Mojžiš J; Solár P
Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
[TBL] [Abstract][Full Text] [Related]
27. Development and application of Hsp90 inhibitors.
Solit DB; Chiosis G
Drug Discov Today; 2008 Jan; 13(1-2):38-43. PubMed ID: 18190862
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90.
Koga F; Kihara K; Neckers L
Anticancer Res; 2009 Mar; 29(3):797-807. PubMed ID: 19414312
[TBL] [Abstract][Full Text] [Related]
29. [Heat shock protein 90: novel target for cancer therapy].
Chen Y; Ding J
Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
[TBL] [Abstract][Full Text] [Related]
30. Hsp90 as a "Chaperone" of the Epigenome: Insights and Opportunities for Cancer Therapy.
Isaacs JS
Adv Cancer Res; 2016; 129():107-40. PubMed ID: 26916003
[TBL] [Abstract][Full Text] [Related]
31. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
Zaarur N; Gabai VL; Porco JA; Calderwood S; Sherman MY
Cancer Res; 2006 Feb; 66(3):1783-91. PubMed ID: 16452239
[TBL] [Abstract][Full Text] [Related]
32. A role for the Hsp90 molecular chaperone family in antigen presentation to T lymphocytes via major histocompatibility complex class II molecules.
Rajagopal D; Bal V; Mayor S; George A; Rath S
Eur J Immunol; 2006 Apr; 36(4):828-41. PubMed ID: 16552710
[TBL] [Abstract][Full Text] [Related]
33. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
Workman P; Burrows F; Neckers L; Rosen N
Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of complement-induced cell lysis: a novel mechanism for the anticancer effects of Hsp90 inhibitors.
Sreedhar AS; Nardai G; Csermely P
Immunol Lett; 2004 Mar; 92(1-2):157-61. PubMed ID: 15081540
[TBL] [Abstract][Full Text] [Related]
35. Natural heat shock protein 90 inhibitors in cancer and inflammation.
Costa TEMM; Raghavendra NM; Penido C
Eur J Med Chem; 2020 Mar; 189():112063. PubMed ID: 31972392
[TBL] [Abstract][Full Text] [Related]
36. Update on Hsp90 inhibitors in clinical trial.
Kim YS; Alarcon SV; Lee S; Lee MJ; Giaccone G; Neckers L; Trepel JB
Curr Top Med Chem; 2009; 9(15):1479-92. PubMed ID: 19860730
[TBL] [Abstract][Full Text] [Related]
37. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy.
Schmitt E; Gehrmann M; Brunet M; Multhoff G; Garrido C
J Leukoc Biol; 2007 Jan; 81(1):15-27. PubMed ID: 16931602
[TBL] [Abstract][Full Text] [Related]
38. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
39. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
[TBL] [Abstract][Full Text] [Related]
40. Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy.
Ren X; Li T; Zhang W; Yang X
Cells; 2022 Aug; 11(16):. PubMed ID: 36010632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
